Soleno Therapeutics, Inc. (NASDAQ: SLNO) related to its sale to Neurocrine Biosciences, Inc. Under the terms of the proposed transaction, Soleno shareholders are expected to receive $53.00 per share in cash.
Soleno Therapeutics, Inc. (NASDAQ: SLNO) related to its sale to Neurocrine Biosciences, Inc. Under the terms of the proposed transaction, Soleno shareholders are expected to receive $53.00 per share in cash.